Immunomic Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.immunomix.com
Clinical Trials
5
Active:1
Completed:4
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05698199
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05422781
- Locations
- 🇺🇸
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device
Phase 1
Completed
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02146781
- Locations
- 🇺🇸
East West Medical Research Institute, Honolulu, Hawaii, United States
A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects
Phase 1
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01966224
- Locations
- 🇺🇸
East West Medical Research Institute, Honolulu, Hawaii, United States
A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid
Phase 1
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Immunomic Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01707069
- Locations
- 🇺🇸
East West Medical Research Institute, Honolulu, Hawaii, United States
News
No news found